Virtual Library

Start Your Search

M.Á. Artal Cortés



Author of

  • +

    MA06 - Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices (ID 379)

    • Event: WCLC 2016
    • Type: Mini Oral Session
    • Track: Locally Advanced NSCLC
    • Presentations: 1
    • +

      MA06.09 - Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin & Chemo-Radiation in Stage III NSCLC. SLCG 10/02 (ID 4238)

      16:00 - 17:30  |  Author(s): M.Á. Artal Cortés

      • Abstract
      • Presentation
      • Slides

      Background:
      This study aims to compare efficacy and safety of two widely used combinations of cisplatin (P) in this setting: as etoposide (E) and vinorelbine. This last, in its oral formulation (oV) which has achieved comparable results as the IV formulation and patients (pts) prefer it.

      Methods:
      Pts between 18-75years, with histologically proven untreated and unresectable locally-advanced NSCLC (LA-NSCLC), adequate respiratory function, V20≤35% and ECOG-PS 0-1, were randomized 1:1 to oV-P arm: 2 induction cycles (cy) of oV-P followed by 2 cy more with RT; or to E-P arm: 2 cy of E-P concomitants to RT. Both arms with a total radiation dose of 66Gy administered 2 Gys daily. Primary endpoint was progression free survival (PFS) by RECIST 1.1. Secondary endpoints: overall response rate (ORR), overall survival (OS) and safety. With α-error of 0.05 (one-tailed test) and 0.1 β-error, median PFS unacceptable for the oV-P arm of 10 months (m) (p0) and a very acceptable of 15 m (p1), 122 eligible pts were required.

      Results:
      140 pts from 23 institutions of SLCG were randomized between 08/2011-12/2014. 134 pts were treated (66 in oV-P and 68 in E-P arms). Results based on this 134 pts are presented. Median age 62 years [39-76]; PS 0/1, 45%/55%; current smoker 51%; squamous cell 51%; stage IIIB 54%. 244 and 131 cy were given in the oV-P and E-P arms, respectively. All irradiated pts in oV-P arm received at least 60Gy, 7 pts in the E-P arm received less than 60Gy (4 due to toxicity). 1 pt (1.5%) in oV-P arm and 12 pts (17.6%) in E-P arm presented esophagitis G3/4 (p=0.002). 121 confirmed eligibility for efficacy analysis. ORR were 39 (64%) and 40 pts (67%) in the oV-P and E-P arms, respectively (p=0.889). After 16 m [1-43] of follow-up, 66% pts progressed and 43% pts died. Median PFS is 11.4 m (IC95%; 6-17) in oV-P arm and 11.8 m (IC95%; 7-16) in E-P arm (p=0.374).

      Conclusion:
      Both regimens achieve similar efficacy however oV-P has less toxicity, especially esophagitis G3/4. Further follow-up is needed for the survival analysis.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.05 - Poster Session with Presenters Present (ID 457)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-005 - Programmed Death-Ligand 1 (PD-L1) in Resected Lung Adenocarcinomas (LA) in a University Hospital (ID 6101)

      14:30 - 15:45  |  Author(s): M.Á. Artal Cortés

      • Abstract

      Background:
      The role of monoclonal antibodies inhibiting of the Programmed Death-1 and its ligand (PD-1/ PD-L1) pathway have been described in advanced disease. The knowledge of the role of this pathway in early stages of lung cancer is still limited. We assessed the incidence of PD-L1 expression in tumour cells of samples of resected lung adenocarcinomas and its prognostic role.

      Methods:
      A retrospective analysis of patients (p) with lung adenocarcinomas radically resected at our Institution between 2004 and 2011 has been conducted. PD-L1 was determined by Immunohistochemistry (SP263, Ventana® assay). A cut-off value of 5% of positive tumour cell was chosen.

      Results:
      112 tumours from 107 p were included. Median age was 62 years. 81% were male, 88% had exposure smoking, baseline performance status was 0 – I – II (62,5% - 26,8% - 10,7%) and pathological stage was I – II – III – IV (49,1% - 26,8% - 23,2% - 0,9%). Fourteen p (12%) expressed PD-L1>5%. They were mostly male (71%), smokers (93%), baseline performance status was 0 – 1 – 2 (64% - 29% - 7%), the most common histological subtype was poorly differentiated adenocarcinoma (64%) and pathological stage was I – II – III (28% - 21% - 50%). One p (7,7%) harboured EGFR mutation, none (0%) were ALK positive and 6 p (46,2%) had a K-RAS mutation. With a follow-up of 52 months median disease free survival (DFS) was 49 months and overall survival (OS) 58 months. Median DFS was shorter in p with expression of PD-L1 (27 months) that in negative tumours (49 months) (p=0,45). Median OS showed a similar pattern (32 vs 66 months respectively) also favouring PD-L1 negative p (p=0,05).

      Conclusion:
      In our series, patients with resected adenocarcinomas expressing PD-L1 in >5% of cells showed a worse disease free and overall survival than patients without such expression.